B7-33 and the Fibrosis Research Story: How a Redesigned Relaxin Peptide Targets Scar Tissue

Fibrosis is the body’s repair system staying switched on for too long. It can leave organs stiff and less able to do their jobs. Researchers are studying B7-33, a redesigned relaxin-family peptide analogue, to understand whether it could influence this process.

The key word is studying. B7-33’s findings so far are from laboratory and animal research, not proof that it treats fibrosis in people. Here, you’ll learn why researchers became interested in it, how its proposed pathway works, and where the evidence stops.

Video placeholder: A short explainer on relaxin, RXFP1 and the difference between normal tissue repair and fibrosis.

Fibrosis: when the repair crew doesn’t clock off

After an injury, your body lays down extracellular matrix (ECM). The supportive framework around cells. Collagen is one of its main building materials. This temporary scaffold helps tissue recover, much like beams and boards help stabilise a construction site.

Usually, the repair crew eventually packs up. In fibrosis, signals that activate collagen-producing cells can persist, so excess matrix builds up and becomes scar tissue. Over time, that tissue may disrupt an organ’s structure and function.

Fibrosis matters in heart, kidney and liver disease because these organs rely on carefully organised tissue. But reducing fibrosis is not as simple as removing every bit of collagen: the body needs matrix for normal structure and repair. The research goal is to restore balance, not switch off healing altogether.

Relaxin’s natural role: remodelling and vascular change

Relaxin is a hormone best known for its role during pregnancy. It helps coordinate changes in connective tissue and blood vessels as the body adapts. It is not simply a “ligament-loosening” signal; its effects involve several tissues and biological pathways. For example, relaxin is associated with vascular changes that support increased blood flow during pregnancy. Human evidence on its relationship to pelvic pain is mixed, so the hormone’s role should not be reduced to one effect.

Think of relaxin as a project manager sending instructions to different work crews. Its effects depend on which cells receive the signal and what other signals are present.

One receptor involved is RXFP1, short for Relaxin Family Peptide Receptor 1. A receptor is like a cell’s receiving station: when a molecule activates it, the cell can pass the message along through internal signalling pathways.

For broader background on relaxin’s antifibrotic research, see this scientific review of relaxin’s anti-fibrotic actions.

Why researchers redesigned the relaxin signal

Natural relaxin is made from two peptide chains held together by disulphide bonds. Researchers developed B7-33 as a single-chain relaxin analogue based on part of relaxin’s B-chain. The idea was to retain selected RXFP1-related antifibrotic effects while changing the way the signal behaves.

One reason for that redesign is signalling selectivity. In the original research, B7-33 showed a different profile from full-length relaxin: it favoured pERK (phosphorylated extracellular signal-regulated kinase, a cell-signalling pathway) rather than producing the same cAMP response, or cyclic adenosine monophosphate, typically measured with RXFP1 activation.

That distinction is scientifically interesting, but it is not a guarantee of a safer or better treatment. The design aimed to separate some desired effects from other relaxin-related actions, including vasodilatory effects. Whether B7-33 reliably avoids reproductive or vascular effects in people has not been established in clinical studies.

How might RXFP1 signalling affect scar tissue?

Fibroblasts are cells that help build and maintain connective tissue. When they become activated, some can turn into myofibroblasts. Cells that produce and organise matrix during repair. If this activity continues, the construction site can become overloaded with collagen.

In preclinical studies, B7-33’s proposed antifibrotic activity involves RXFP1 signalling and pERK. Researchers have also reported increased MMP-2, or matrix metalloproteinase-2, an enzyme involved in breaking down components of the ECM. In simple terms, the theory is that the signal may influence both sides of the balance: how matrix is built and how it is remodelled.

Some proposed pathway details, including interactions with other receptors and downstream signals, remain under investigation. A pathway diagram can show a plausible chain of events; it cannot, on its own, show that a compound improves health in humans.

What has been studied in organs?

Heart: Animal studies have examined B7-33 in models of cardiac injury and fibrosis. Research has reported reduced collagen deposition or other changes related to cardiac remodelling in particular experimental settings. These findings make the heart an important research area, but animal outcomes do not establish treatment effects in people.

Kidney: Researchers have also investigated B7-33 in renal fibrosis models, including experimental obstruction-related injury. In these studies, measures of matrix remodelling and fibrosis were explored. Kidney evidence is still preclinical, and it should not be confused with proof that B7-33 treats chronic kidney disease.

Liver: Liver fibrosis is a significant research target because ongoing injury can lead to excess scar tissue and impaired function. Relaxin biology has been studied in liver-fibrosis research, but findings about natural or full-length relaxin should not automatically be presented as evidence for B7-33. The evidence for B7-33 itself is narrower; no human liver-fibrosis benefit has been established.

Video placeholder: A researcher-led overview of the B7-33 evidence, separating cell studies, animal models and human clinical evidence.

The evidence boundary, and the safety boundary

The central limitation is straightforward: preclinical findings are not clinical proof. Cell experiments and animal models help researchers examine mechanisms and decide what to investigate next. They do not establish an effective dose, long-term safety, or benefit for people with heart, kidney or liver disease.

B7-33 is not an established self-treatment. Do not use it to manage a diagnosed condition or replace prescribed care. If you have concerns about fibrosis or organ health, speak with a qualified clinician. In Australia, check the Therapeutic Goods Administration (TGA) and the Australian Register of Therapeutic Goods (ARTG) for a product’s regulatory status; a research listing is not evidence of therapeutic approval.

WL Australia lists B7-33 10 mg as a research product and states “not for human use.” That warning matters. Read the listing carefully and do not interpret it as medical advice or a recommendation to self-treat.

Where this article fits with earlier B7-33 coverage

This article focuses on fibrosis and cardiac research rather than repeating a general peptide overview. For the earlier B7-33 spotlight, Injury Recovery Trio article, and four-peptide comparison, visit the WL Australia blog archive.

B7-33 offers researchers an intriguing question: can a redesigned relaxin signal influence scar-tissue remodelling while producing a different signalling profile? Early studies provide reasons to investigate, but not a clinical answer. For now, the responsible summary is promising preclinical research, meaningful evidence limits, and no basis for self-treatment.